Entera Bio to Present at BTIG’s Virtual Biotechnology Conference
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:30 p.m. EDT. The event will be available via a live webcast on the company's Investor Relations page. A replay will be accessible for 45 days post-presentation.
Entera specializes in orally delivered macromolecule therapeutics addressing significant medical needs, particularly for patients who struggle with injectable therapies. Their leading candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 clinical development.
- None.
- None.
BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:30 p.m. EDT.
To access a live webcast of the fireside chat on the “Investor Relations” page of Entera’s website, please click here. A replay of the webcast will be archived on Entera’s website for approximately 45 days following the presentation.
About Entera Bio
Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
FAQ
What event is Entera Bio participating in on August 10, 2020?
What time will Entera Bio's presentation start at the BTIG Biotechnology Conference?
How can I access the live webcast of Entera Bio's conference presentation?
How long will the replay of the Entera Bio webcast be available?
What are the main products Entera Bio is developing?
